ATYR PHARMA INC (LIFE) Stock Analyst Ratings
USA - NASDAQ:LIFE - US0021202025 - Common Stock
1.9 USD
+0.05 (+2.7%)
1.94 USD
+0.04 (+2.11%)
ChartMill assigns a Buy % Consensus number of 82% to LIFE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 25.09. This target is 1220.63% above the current price.
LIFE was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LIFE.
In the previous month the buy percentage consensus was at a similar level.
LIFE was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-03-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-21 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-07-05 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-05-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | RBC Capital | Reiterate | Outperform |
| 2023-04-11 | Piper Sandler | Maintains | Overweight |
| 2023-03-10 | RBC Capital | Reiterate | Outperform |
| 2023-03-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-06 | Roth MKM | Reiterate | Buy |
| 2023-03-02 | RBC Capital | Maintains | Outperform |
| 2023-02-07 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-08-16 | Piper Sandler | Maintains | Overweight |
| 2022-07-21 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-18 | Piper Sandler | Maintains | Overweight |
| 2022-05-10 | RBC Capital | Maintains | Outperform |
| 2021-11-11 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-12 | RBC Capital | Initiate | Outperform |
| 2021-09-21 | Piper Sandler | Initiate | Overweight |
| 2021-09-14 | Oppenheimer | Maintains | Outperform |
| 2021-09-14 | Roth Capital | Maintains | Buy |
| 2021-09-13 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-18 | JonesTrading | Initiate | Buy |
| 2021-03-24 | Oppenheimer | Maintains | Outperform |
ATYR PHARMA INC / LIFE FAQ
What is the average price target for ATYR PHARMA INC (LIFE) stock?
11 analysts have analysed LIFE and the average price target is 25.09 USD. This implies a price increase of 1220.63% is expected in the next year compared to the current price of 1.9.
What is the consensus rating for LIFE stock?
The consensus rating for ATYR PHARMA INC (LIFE) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.